Valuation: HighTide Therapeutics, Inc.

Market Cap 1.31B 193M 170M 158M 145M 272M 18.59B 276M 1.87B 732M 9.14B 725M 709M 31.6B P/E 2024
-1.41x
P/E 2025 -5.19x
Enterprise Value 931M 138M 121M 112M 103M 194M 13.24B 197M 1.33B 521M 6.51B 516M 505M 22.51B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
44.17%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 56 31/12/2010
Director of Finance/CFO 57 30/11/2022
Chief Tech/Sci/R&D Officer - 01/02/2026
Director TitleAgeSince
Director/Board Member 68 29/11/2020
Director/Board Member 61 -
Chairman 56 -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 193M
+0.93%+6.97%+62.83%+67.97% 57.28B
-1.92%+6.03%+43.68%+84.56% 54.99B
-0.46%-1.29%+3.28%+422.58% 23.18B
-2.97%-2.35%-22.03%-16.54% 22.59B
-0.36%+5.73%+30.99%-3.58% 20.46B
-1.34%+0.51%+25.02%-30.27% 17.56B
-1.44%+5.67%+32.54%+544.11% 15.67B
-1.30%-5.02%+165.62%+291.37% 14.46B
-0.50%-0.98%+23.62%+178.38% 13.92B
Average -0.94%+1.28%+40.62%+170.95% 26.68B
Weighted average by Cap. -0.87%+2.10%+41.18%+135.69%

Financials

2024 2025
Net sales - -
Net income -382M -56.39M -49.52M -46.06M -42.26M -79.41M -5.43B -80.63M -547M -214M -2.67B -212M -207M -9.23B -245M -36.18M -31.78M -29.55M -27.12M -50.95M -3.48B -51.74M -351M -137M -1.71B -136M -133M -5.92B
Net Debt -413M -60.97M -53.55M -49.8M -45.69M -85.86M -5.87B -87.18M -591M -231M -2.89B -229M -224M -9.98B -376M -55.53M -48.77M -45.35M -41.62M -78.2M -5.35B -79.4M -539M -210M -2.63B -208M -204M -9.09B
Logo HighTide Therapeutics, Inc.
HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The Company has developed a product pipeline of multiple product candidates in-house, covering many indications in metabolic and digestive diseases among which, some are at clinical-stage. The Company’s core product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases. The Company conducts operations in the United States, Mainland China, Hong Kong and Australia.
Employees
51